Rockefeller Capital Management’s Novavax NVAX Stock Holding History

Rockefeller Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.7K	Sell	4,211 -1,422	-25%	-$12.7K	﹤0.01%	3467
2026 Q1	$45.9K	Buy	5,633 +2,078	+58%	+$18.8K	﹤0.01%	3324
2025 Q4	$23.9K	Buy	3,555 +694	+24%	+$5.23K	﹤0.01%	3434
2025 Q3	$24.8K	Buy	+2,861	New	+$22.3K	﹤0.01%	3248
2023 Q1	–	Sell	-1,333	Closed	-$13K	–	3247
2022 Q4	$13K	Hold	1,333	–	–	﹤0.01%	2970
2022 Q3	$24K	Sell	1,333 -243	-15%	-$10.5K	﹤0.01%	2699
2022 Q2	$81K	Buy	1,576 +1,240	+369%	+$64.2K	﹤0.01%	2056
2022 Q1	$24K	Sell	336 -50	-13%	-$4.46K	﹤0.01%	2642
2021 Q4	$55K	Buy	386 +149	+63%	+$25.6K	﹤0.01%	2173
2021 Q3	$49K	Sell	237 -2	-0.8%	-$441	﹤0.01%	2150
2021 Q2	$50K	Buy	239 +3	+1%	+$550	﹤0.01%	2076
2021 Q1	$42K	Buy	236 +28	+13%	+$5.58K	﹤0.01%	1962
2020 Q4	$23K	Buy	+208	New	+$22.1K	﹤0.01%	1955
2020 Q2	–	Sell	-235	Closed	-$3K	–	2654
2020 Q1	$3K	Buy	+235	New	+$1.99K	﹤0.01%	2101

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Rockefeller Capital Management's NVAX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Novavax (NVAX) stake by 25% in Q2 2026, selling an estimated $12.7K and leaving 4,211 shares worth $39.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3467.

Rockefeller Capital Management first reported a position in NVAX in Q1 2020 and has held it in 14 quarters since. The position peaked at $81K in Q2 2022. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Rockefeller Capital Management held 4,211 shares of Novavax worth $39.7K as of Q2 2026.
Rockefeller Capital Management sold 1,422 Novavax shares in Q2 2026, an estimated $12.7K.
Novavax made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3467 holding.
Rockefeller Capital Management first reported a position in Novavax in Q1 2020 and has held it in 14 quarters since.
Rockefeller Capital Management's Novavax position peaked at $81K in Q2 2022.
266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.